



Published in final edited form as:

Genet Med. 2021 May ; 23(5): 881–887. doi:10.1038/s41436-020-01076-8.

Variants in *GNAI1* Cause a Syndrome Associated with Variable Features including Developmental Delay, Seizures and Hypotonia

A full list of authors and affiliations appears at the end of the article.

Abstract

Purpose: Neurodevelopmental disorders (NDDs) encompass a spectrum of genetically heterogeneous disorders with features that commonly include developmental delay, intellectual disability, and autism spectrum disorders. We sought to delineate the molecular and phenotypic spectrum of a novel neurodevelopmental disorder caused by variants in the *GNAI1* gene.

Methods: Through large cohort trio-based exome sequencing and international data-sharing, we identified 24 unrelated individuals with NDD phenotypes and a variant in *GNAI1*, which encodes the inhibitory G α 1 subunit of heterotrimeric G-proteins. We collected detailed genotype and phenotype information for each affected individual.

Results: We identified 16 unique variants in *GNAI1* in 24 affected individuals; 23 occurred *de novo* and one was inherited from a mosaic parent. Most affected individuals have a severe neurodevelopmental disorder. Core features include global developmental delay, intellectual disability, hypotonia, and epilepsy.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Correspondence to: Heather C. Mefford, MD, PhD, hmefford@uw.edu, [@hmefford](https://twitter.com/hmefford).

*These authors contributed equally

Conceptualization: L.R., A.M.M., J.F.G., V.C.V., H.C.M. ; Data curation: A.M.M., J.F.G., R.H.J., I.M.L., J.J.S., G.N.W., H.D., E.M.G., L.Z., C.B., J.M., M.S., A.A., A.A., M.M., A.G., C.B., R.C.C., T.M., C.M., S.M., C.P., P.C.V., A.F.B., S.J., C.T., G.N., M.T., L.B., M.Z., S.A.S.V., B.M., L.S., B.E.H., K.S., D.D., D.J.H., I.M.W., R.E.S., K.G.M., J.J., L.R., W.B.D., F.L., A.G., T.P., S.A., K.P., C.K., T.L.H., D.G.M., M.C.O., G.E.V., E.E., V.C.V., H.C.M.; Formal Analysis: L.R., A.M.M., J.F.G., V.C.V., H.C.M.; Writing – original draft: A.M.M., J.F.G., H.C.M.; Writing – review & editing: R.H.J., A.M.M., J.F.G., H.C.M.

Web Resources

gnomAD v2.1.1: <https://gnomad.broadinstitute.org/>

CADD: <http://cadd.gs.washington.edu/>

FoldX suite: <http://foldxsuite.crg.eu/>

GeneMatcher: <https://www.genematcher.org/>

MyGene2: <https://mygene2.org/MyGene2/>

Matchmaker Exchange: <https://www.matchmakerexchange.org/>

M-CAP Score: <http://bejerano.stanford.edu/mcap/>

OMIM: <https://www.omim.org/>

Ethics Declaration

This study was approved by local institutional review boards of the participating centers (University of Washington and UK Ethics Research Committee). Informed consent was obtained from all individuals or was provided by a parent or legal guardian in the case of minors or individuals with intellectual disability. Their permission for inclusion in this case series, including photographs, was obtained locally.

Conflict of Interest

IMW, RES, KGM, JJ, and LR are employees of GeneDx, Inc. The other authors declare no conflicts of interest.

Conclusion: This collaboration establishes *GNAI1* variants as a cause of NDDs. *GNAI1*-related NDD is most often characterized by severe to profound delays, hypotonia, epilepsy that ranges from self-limiting to intractable, behavior problems, and variable mild dysmorphic features.

Introduction

Neurodevelopmental disorders (NDDs) are heterogeneous disorders, often with a broad and overlapping range of features that commonly include developmental delay, intellectual disability, and autism spectrum disorder. This group of disorders also has an increased incidence of comorbidities such as epilepsy. Advances in genomic technologies have led to an exponential increase in the number of genes associated with NDDs. However, up to half of those affected do not have an identified genetic etiology¹, presenting challenges in understanding the long-term prognosis and accessing appropriate support. Phenotype-based genetic investigations of NDDs are hampered by the highly variable clinical manifestations, the phenotypic overlap with other closely related disorders, and the rarity of particular genetic subtypes². Instead, more recently, large-scale trio-based exome sequencing of clinically heterogeneous populations coupled with international data-sharing has proven a powerful strategy for discovering NDD-associated genes^{1, 2}.

G-protein subunits belong to a family of proteins that have previously been associated with NDDs^{3, 4}. Heterotrimeric G proteins, composed of α , β and γ subunits, transmit the signals of extracellular ligands bound to G-protein-coupled receptors (GPCRs) to intracellular signaling pathways⁵. G-protein signaling has been implicated in a diverse range of biological functions including neuronal development and synaptic function⁶. *GNAI1* (MIM 139310) encodes the inhibitory G α i1 subunit of heterotrimeric G-proteins. A recent study found a significant enrichment of *de novo* variants in *GNAI1* in a diverse cohort of individuals with NDDs^{2, 7}. Here, we describe 24 unrelated individuals with *GNAI1* variants (23 *de novo* variants and one inherited from a mosaic parent) and delineate the associated phenotypic features which include global developmental delay with intellectual disability, hypotonia, and seizures.

Methods

Individuals with pathogenic and likely pathogenic variants in *GNAI1* (NM_002069.5) were identified via Deciphering Developmental Disorders study (DDD) research study⁷ and international collaboration facilitated by GeneMatcher⁸ and MyGene2. Variants were classified using American College of Medical Genetics guidelines⁹. Individuals were identified via trio exome sequencing by the Deciphering Developmental Disorders study⁷ (individuals 11, 14, 16, 18-20, and 24), clinical trio exome sequencing at GeneDx as previously described¹⁰ (1-3, 5, 7-10, 15, 17, 22-23), trio exome sequencing via clinical practice (4, 6, 12), or by research-based trio exome sequencing (13, 21). The genetic details from thirteen of these individuals was previously reported (2, 3, 7-11, 14, 16, 18-20, 24) with minimal clinical details^{2, 7}; we obtained additional, detailed clinical information for these individuals for this study.

Results

We identified 27 unrelated individuals (16 female) with rare variants in *GNAII* (GenBank: [NM_002069.6](#)). For three individuals with *GNAII* variants, parental samples were unavailable for testing (Table S1); clinical information for these individuals has not been included in this report. The remaining twenty-four variants would meet the criteria to be classified as likely pathogenic or pathogenic according to ACMG guidelines if *GNAII* were an established disease gene⁹ (Figure 1, Table 1). Of these, twenty-three variants were *de novo* in the affected individual (somatic mosaicism in Individual 2), while one variant was inherited from a mother with low-level mosaicism (Individual 3, 6.0% alternate allele frequency). Where applicable, *de novo* status of variants and parental relationships were confirmed.

Among the 24 individuals with variants in *GNAII*, there were 16 unique variants, with seven recurrent variants identified in two or three individuals each. At three residues (Gly40, Thr48, Lys270), there were two different pathogenic variants resulting in different amino acid changes. Of the 16 variants, 12 were missense variants, three were small in-frame deletions, and one was a protein-truncating variant. The majority of missense and coding deletion variants (9/15; 60%) affect amino acids within the guanine nucleotide binding motifs of *GNAII* (Figure 1). Variants predominantly cluster in the first GDP binding motif (also known as the Walker A motif or P-loop), where five variants at three sites (Gly40, Gly45, and Thr48) accounted for 10/24 individuals (42%), while variants at Arg270 and Ala326 affect residues in the fourth and fifth guanine nucleotide binding motifs, respectively.

We performed detailed phenotyping of the 24 affected individuals with *de novo GNAII* variants (Table 2, Table S1). Age at last medical review ranged from 3 years 10 months to 18 years (median age 11 years). All participants have global developmental delays ranging in severity from mild to profound. Speech is significantly affected with language delays reported in 21/23 (91%) individuals; 16 individuals are nonverbal (at ages 3–18 years), and only one individual has achieved fluent speech. Gross motor delays are also common. Delayed sitting was reported in 18/21 (86%) individuals, five of whom cannot yet sit independently (at ages 18 months–18 years). Delayed walking was reported in 19/23 (83%) individuals; nine individuals remain nonambulatory (ages 18 months–18 years). Intellectual disability was reported in all individuals for whom data was available (20/20) and ranged from mild (3/20; 15%) to severe/profound (11/20; 55%).

Other prominent phenotypic features include hypotonia (20/23 individuals, 87%), and epilepsy (17/23 individuals, 74%) individuals. For many patients, hypotonia was severe and had a significant effect on daily functioning. Median age of seizure onset was 5 months (range 36 hours to 7 years), with seizures beginning in the first six months of life in 10/15 (67%) individuals for whom data were available. Seizure types were variable with the most common being absence seizures (n=5), generalized tonic-clonic seizures (n=5), and focal onset impaired awareness seizures (n=4).

While behavioral anomalies were present in 17/19 individuals (89%), they were variable across the cohort. The most common behavioral features included aggression and temper tantrums (n=7), autism (n=7), hypersensitivity (n=5), and hand stereotypies (n=6). Other variable features included feeding difficulties (n=9) and obesity (n=7). MRI abnormalities were reported for 10/20 (50%) individuals, with the most common finding being brain atrophy seen in four individuals.

Dysmorphic features were reported in 16/21 (76%) individuals (Figure 2); however, the described physical features were variable. The most commonly reported features included tapered fingers (n=9), a markedly long hallux (n=5), and a short, upturned nose (n=8). Other common facial features included a tented upper lip or open mouth appearance (n=5), and a thin upper lip or prominent lower lip (n=4).

Discussion

We describe a novel, severe neurodevelopmental disorder due to *de novo* variants in the *GNAI1* gene, which encodes G α i1, a member of the Gi/o inhibitory family of G-protein α -subunits. Heterotrimeric G-proteins act as a molecular switch. The GDP-bound G α subunit binds the G $\beta\gamma$ dimer, maintaining the heterotrimeric protein in an inactive state. In response to an extracellular stimulant, bound GDP is replaced by GTP, resulting in a conformational change leading to the disassociation of the G α subunit from the G $\beta\gamma$ dimer. Once separated, the G α subunit and the G $\beta\gamma$ dimer are able to activate (or inhibit) downstream signaling pathways via modulation of cAMP levels. The intrinsic GTPase activity of the G α subunit will eventually result in GTP hydrolysis, returning the protein to its GDP-bound inactive heterotrimeric state⁵.

G α i1 is part of the Gi/o inhibitory family of α -subunits named for their ability to inhibit adenylyl cyclase activity. In the central nervous system, G α i1 has been shown to mediate major signaling pathways Akt-mTORC1 and Erk-MAPK^{11, 12} and control the gating of G protein-activated potassium channels¹³. Other G-protein subunits have also been implicated in neurological disease including *GNAQ* (MIM: 600998) associated with Sturge-Weber syndrome, *GNAL* (MIM: 139312) associated with dystonia, *GNAOI* (MIM: 139311) in which loss of function variants are associated with developmental and epileptic encephalopathy while gain of function variants are associated with movement disorders¹⁴, and *GNBI* (MIM: 139380) associated with developmental delay. Individuals with loss of function variants in *GNBI*, a β -subunit of heterotrimeric G-proteins, have a strikingly similar phenotype to individuals with *de novo* *GNAI1* variants, including profound developmental delay commonly accompanied by hypotonia and seizures⁴, suggesting there may be a common pathogenetic disease mechanism between *GNBI* and *GNAI1*.

G α proteins contain five highly conserved guanine nucleotide binding motifs that fold to form a single deep pocket for binding guanine nucleotides¹⁰. Of the 16 pathogenic or likely pathogenic variants in *GNAI1* reported in this study and one previously reported variant (p.Lys46Glu)², nine variants at six sites (Gly40, Gly45, Lys46, Thr48, Lys270, and Ala326) are located in the guanine nucleotide binding pocket of *GNAI1* (Figure 1). Gly40, Gly45, Lys46, and Thr48 reside in the highly conserved first GDP binding motif. Gly40 lies at the

mouth of the nucleotide binding pocket immediately N-terminal to a series of GDP-interacting residues, including Gly45 and Thr48. Notably, although Arg270 and Ala326 are distant in the linear sequence to Gly45 and Thr48, they lie in close spatial proximity on the opposite face of the GDP binding pocket¹¹. Gly45, Thr48, and Lys270 make direct contacts with the GDP ligand and therefore the Gly45Asp, Thr48Lys, Thr48Ile, Lys270Asn, and Lys270Arg substitutions are likely to disrupt these interactions. While Gly40 does not directly interact with the GDP ligand, structural modeling predicts that the Gly40Arg and Gly40Cys substitutions will have a significant destabilizing effect on the GDP binding pocket (increases in free energy compared to the native structure of ~9.4 kcal/mol and ~27.6 kcal/mol respectively; values >3 kcal/mol are generally regarded as strongly destabilizing¹⁵). As such, the pathogenic variants in guanine nucleotide binding motifs of Gai1 are all predicted to have adverse effects on Gai1 function through the disruption of Gai1 ability to bind GDP and GTP and/or hydrolyze GTP.

GNAI1 is predicted to be intolerant to loss of function variants (pLI=0.91; e/o= 0.12 [0.05 - 0.38])¹⁶. Of the 16 variants in *GNAI1* identified in 24 individuals, only one was a truncating variant: p.(Ile278Asnfs*20) frameshift identified in a single individual with profound developmental delay, axial hypotonia, and seizures; this variant is located within the last 50bp of the penultimate exon and is predicted to escape nonsense-mediated decay. We identified one additional individual with an early truncating variant, but inheritance information was not available (Supplementary Table 1). We also previously identified large, heterozygous deletions encompassing *GNAI1* (and additional genes) in two unrelated individuals with epilepsy¹⁷. In one case, the deletion segregated in a large family, with at least 5 affected individuals in 3 generations; all had variable types of generalized epilepsy (ranging from mild to severe) and learning difficulties. Additional individuals with truncating variants need to be identified in order to determine if there are differences in phenotypes between individuals with missense and truncating variants in *GNAI1*.

GNAI1-related NDD is most often characterized by severe to profound delays, hypotonia, epilepsy that ranges from self-limiting to intractable, behavior problems, and variable mild dysmorphic features, though there is range of severity for all phenotypic features associated with pathogenic variants in *GNAI1*. Like many NDDs that have been recently described, *GNAI1*-related disorder may not be distinctly recognizable; many features overlap with other single-gene disorders including *GNB1*⁴, *PPP3CA*¹⁸, *TANC2*¹⁹ and others. While many individuals have severe developmental delay accompanied by several additional comorbidities, there are also some more mildly affected individuals. In some cases, additional genetic variants may contribute to the phenotype; for example, individual 9 has a *de novo*, likely pathogenic variant in *ACTA1*, which can cause myopathy and may contribute to hypotonia or club feet in this case. Although we identified seven recurrent variants, our cohort is too small to determine whether there are clear genotype-phenotype correlations. The two individuals with p.(Lys270Arg) variants (individuals 19 and 20) have similar presentations, with similar ages at sitting and walking, development of some speech, and seizures. In contrast, for the two individuals with p.(Gln172del) variants, one is nonverbal, nonambulatory and has intractable seizures (individual 13), while the other (individual 14) is ambulatory, has aggressive behaviors and has not had seizures. This lack of clear genotype-

phenotype correlation will make it difficult to predict the severity of the disease progression in newly diagnosed individuals.

In summary, we report 24 individuals with *de novo* variants in *GNAII* and a neurodevelopmental disorder characterized by global developmental delay, intellectual disability, hypotonia, and seizures. While there is a spectrum of severity associated with pathogenic variants in *GNAII*, most individuals are profoundly affected. Identification of additional cases as well systematic studies that implement uniform tools to evaluate phenotypes such as behavior and cognitive functioning will provide further insight into the full spectrum of neurological features associated with *GNAII* and potentially elucidate subtle genotype-phenotype correlations not apparent in this cohort.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Alison M. Muir, PhD^{1,*}, Jennifer F. Gardner, MBChB, MRCPCH^{2,*}, Richard H. van Jaarsveld, PhD³, Iris M. de Lange, MD, PhD³, Jasper J. van der Smagt, MD³, Golder N. Wilson, MD, PhD⁴, Holly Dubbs, MS⁵, Ethan M. Goldberg, MD, PhD⁵, Lia Zitano, MS⁶, Caleb Bupp, MD⁶, Jose Martinez, MD⁷, Myriam Srour, MDCM, PhD⁸, Andrea Accogli, MD⁸, Afnan Alhakeem, MD⁸, Meira Meltzer, MA, MS⁹, Andrea Gropman, MD⁹, Carole Brewer, MBBS, MRCP¹⁰, Richard C. Caswell, PhD¹¹, Tara Montgomery, MD¹², Caoimhe McKenna, MBBS, MSc¹³, Shane McKee, MD¹³, Corinna Powell, MBChB, MRCPCH¹⁴, Pradeep C. Vasudevan, MBBS, FRCP¹⁴, Angela F. Brady, MBChB, PhD¹⁵, Shelagh Joss, MBChB, MRCPCH¹⁶, Carolyn Tysoe, BSc (Hons), PhD¹⁷, Grace Noh, MD¹⁸, Mark Tarnopolsky, MD, PhD¹⁹, Lauren Brady, MSc¹⁹, Muhammad Zafar, MBBS²⁰, Samantha A. Schrier Vergano, MD²¹, Brianna Murray, MS²¹, Lindsey Sawyer, MA, MS²¹, Bryan E. Hainline, MD, PhD²², Katherine Sapp, MS²², Danielle DeMarzo, MD²³, Darcy J. Huismann, MS²³, Ingrid M. Wentzensen, MD²⁴, Rhonda E. Schnur, MD²⁴, Kristin G. Monaghan, PhD²⁴, Jane Juusola, PhD²⁴, Lindsay Rhodes, MS²⁴, William B. Dobyns, MD^{1,25}, Francois Lecoquierre, MD²⁶, Alice Goldenberg, MD²⁶, Tilman Polster, MD²⁷, Susanne Axer-Schaefer, MD²⁷, Konrad Platzer, MD²⁸, Chiara Klöckner²⁸, Trevor L. Hoffman, MD²⁹, Daniel G. MacArthur, PhD^{30,31}, Melanie C. O'Leary, MS³⁰, Grace E. VanNoy, MS³⁰, Eleina England, MS³⁰, Vinod C. Varghese, MD², Heather C. Mefford, MD, PhD¹

Affiliations

¹Department of Pediatrics, Division of Genetic Medicine, University of Washington, Seattle WA 98195 ²All Wales Medical Genomics Service, Cardiff, United Kingdom ³Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands ⁴Texas Tech Health Science Center, Lubbock and KinderGenome Medical Genetics, Dallas TX ⁵Department of Pediatrics, Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA ⁶Spectrum Health Medical

Genetics, Grand Rapids, MI ⁷Department of Pediatrics and Adolescent Medicine, Division of Genetics, University of South Alabama, Mobile AL ⁸Department of Pediatrics, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC ⁹Department of Neurology, Children's National Hospital, Washington DC ¹⁰Royal Devon and Exeter NHS Foundation Trust ¹¹Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, EX2 5DW, UK; and Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, EX2 5DW, UK ¹²Newcastle upon Tyne Hospitals NHS Foundation Trust ¹³Northern Ireland Regional Genetics Service, UK ¹⁴University Hospitals of Leicester NHS Trust Leicester Royal Infirmary Leicester, UK ¹⁵North West Thames Regional Genetics Service, Northwick Park and St. Mark's Hospitals, Watford Road, Harrow, HA1 3UJ, UK ¹⁶NHS Greater Glasgow and Clyde, Scotland, UK ¹⁷Royal Devon and Exeter NHS Foundation Trust ¹⁸Department of Genetics, Southern California Kaiser Permanente Medical Group, Pasadena, CA 91103 ¹⁹Department of Pediatrics, Division of Neuromuscular and Neurometabolic Disorders, McMaster Children's Hospital, Hamilton, ON, CANADA, L8N3Z5 ²⁰Duke University Health System, Durham NC ²¹Children's Hospital of The King's Daughters, Norfolk, Virginia ²²Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN ²³Department of Pediatrics, Section of Genetics, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma ²⁴GeneDx, Inc., Gaithersburg, MD ²⁵Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA 98105 ²⁶Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France ²⁷Paediatric Epileptology Krankenhaus Mara Bethel Epilepsy Centre Bielefeld, Germany ²⁸Institute of Human Genetics, University of Leipzig Medical Center, 04109 Leipzig, Germany ²⁹Department of Genetics, Southern California Kaiser Permanente Medical Group, Pasadena, CA 91103 ³⁰Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA ³¹Centre for Population Genomics, Garvan Institute of Medical Research, and University of New South Wales Sydney, Sydney, Australia; Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia

Acknowledgements

We thank all affected individuals and their families for participating in this study. AMM received support from the American Epilepsy Society. HCM received support from the National Institute of Neurological Disorders and Stroke (R01 NS069605). FL and AG received funding from European Union and Région Normandie in the context of Recherche Innovation Normandie (RIN 2018). Europe gets involved in Normandie with the European Regional Development Fund (ERDF). Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and was funded by the National Human Genome Research Institute, the National Eye Institute, and the National Heart, Lung and Blood Institute grants UM1 HG008900, R01 HG009141 and by the Chan Zuckerberg Initiative to the Rare Genomes Project. The DDD study presents independent research commissioned by the Health Innovation Challenge Fund (grant number HICF-1009-003). This study makes use of DECIPHER (<http://decipher.sanger.ac.uk>), which is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement.

Data Availability

All methods and data are available on request.

References

1. Deciphering Developmental Disorders S. Large-scale discovery of novel genetic causes of developmental disorders *Nature*. 2015 3 12;519:223–228. [PubMed: 25533962]
2. Kaplanis J, Samocha KE, Wiel L, Zhang Z, Arvai KJ, Eberhardt RY, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data *Nature*. 2020 10;586:757–762. [PubMed: 33057194]
3. Nakamura K, Kodera H, Akita T, Shiina M, Kato M, Hoshino H, et al. De Novo mutations in GNAO1, encoding a Galphao subunit of heterotrimeric G proteins, cause epileptic encephalopathy *American journal of human genetics*. 2013 9 5;93:496–505. [PubMed: 23993195]
4. Petrovski S, Kury S, Myers CT, Anyane-Yeboah K, Cogne B, Bialer M, et al. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures *American journal of human genetics*. 2016 5 5;98:1001–1010. [PubMed: 27108799]
5. McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS. G-protein signaling: back to the future *Cellular and molecular life sciences : CMLS*. 2005 3;62:551–577. [PubMed: 15747061]
6. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, et al. The G protein-coupled receptor repertoires of human and mouse *Proceedings of the National Academy of Sciences of the United States of America*. 2003 4 15;100:4903–4908. [PubMed: 12679517]
7. Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders *Nature*. 2017 2 23;542:433–438. [PubMed: 28135719]
8. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene *Human mutation*. 2015 10;36:928–930. [PubMed: 26220891]
9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology *Genet Med*. 2015 5;17:405–424. [PubMed: 25741868]
10. Retterer K, Jussola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications *Genetics in medicine : official journal of the American College of Medical Genetics*. 2016 7;18:696–704. [PubMed: 26633542]
11. Cao C, Huang X, Han Y, Wan Y, Birnbaumer L, Feng GS, et al. Galpha(i1) and Galpha(i3) are required for epidermal growth factor-mediated activation of the Akt-mTORC1 pathway *Science signaling*. 2009 4 28;2:ra17. [PubMed: 19401591]
12. Marshall J, Zhou XZ, Chen G, Yang SQ, Li Y, Wang Y, et al. Antidepressant action of BDNF requires and is mimicked by Galphai1/3 expression in the hippocampus *Proceedings of the National Academy of Sciences of the United States of America*. 2018 4 10;115:E3549–E3558. [PubMed: 29507199]
13. Peleg S, Varon D, Ivanina T, Dessauer CW, Dascal N. G(alpha)(i) controls the gating of the G protein-activated K(+) channel, GIRK *Neuron*. 2002 1 3;33:87–99. [PubMed: 11779482]
14. Feng H, Sjogren B, Karaj B, Shaw V, Gezer A, Neubig RR. Movement disorder in GNAO1 encephalopathy associated with gain-of-function mutations *Neurology*. 2017 8 22;89:762–770. [PubMed: 28747448]
15. Tokuriki N, Stricher F, Schymkowitz J, Serrano L, Tawfik DS. The stability effects of protein mutations appear to be universally distributed *J Mol Biol*. 2007 6;369:1318–1332. [PubMed: 17482644]
16. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans *Nature*. 2016 8 18;536:285–291. [PubMed: 27535533]
17. Mefford HC, Yendle SC, Hsu C, Cook J, Geraghty E, McMahon JM, et al. Rare copy number variants are an important cause of epileptic encephalopathies *Annals of neurology*. 2011

12;70:974–985. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't [PubMed: 22190369]

18. Myers CT, Stong N, Mountier EI, Helbig KL, Freytag S, Sullivan JE, et al. De Novo Mutations in PPP3CA Cause Severe Neurodevelopmental Disease with Seizures *Am J Hum Genet.* 2017 10;101:516–524. [PubMed: 28942967]
19. Guo H, Bettella E, Marcogliese PC, Zhao R, Andrews JC, Nowakowski TJ, et al. Disruptive mutations in TANC2 define a neurodevelopmental syndrome associated with psychiatric disorders *Nat Commun.* 2019 10;10:4679. [PubMed: 31616000]




Figure 1: Distribution of disease-causing variants across GNAI1.

A) Schematic showing the pathogenic and likely pathogenic variants identified in GNAI1, including one previously reported variant (*) (Kaplanis et al. 2020). Variants cluster within the first guanine nucleotide-binding domain (green box). Missense variants are represented as brown diamonds, coding deletion variants as blue circles, and the truncating frameshift variant as a yellow star. Each symbol represents one individual. B) 3D structure of GNAI1. The left figure shows the structure of GNAI1 as part of the trimeric G-protein complex (PDB accession 6crk); GNAI1 is shown as a cyan ribbon, except for positions of novel variants which are coloured as follows: missense, magenta; in-frame deletions, yellow; frameshifting insertion at Ile278, light green; bound GDP is shown as space-filling spheres, coloured by atom type (white, carbon; blue, nitrogen; red, oxygen; orange, phosphorus); the molecular surface is shown for the $\beta\gamma$ dimer, with the $\beta1$ and $\gamma2$ chains coloured dark green and orange respectively. The right figure shows GNAI1 only, rotated around the vertical axis; Gly45 is obscured by the GDP ligand in this view. In both parts, labelling in bold font indicates residues making direct contact with GDP (Gly45, Thr48, Lys270, Ala326).



Figure 2: Photographs of affected individuals.

A) individual 2; B) individual 10; C) individuals 11; D) individual 16; E) individual 18; F, individual 19; G) individual 20; H) individual 22; I) individual 23; J) individual 24. Affected individuals have variable minor dysmorphic features and tend to have tapering fingers.

Table 1:

de novo variants in *GNAI1*

Ind.	Variant			Protein Domain	CADD	M-CAP score (prediction)	phastCons 100way vertebrate	gnomAD AC
	Genomic Coordinates (GRCh37/hg19)	cDNA Position (NM_002069)	Protein Position					
1 2	chr7:g.79764594G>C	c.118G>C	p.(Gly40Arg)	GDP Binding, GoLoco Binding	33	0.910 (PP)	9.041	0
3 4	chr7:g.79764594G>T	c.118G>T	p.(Gly40Cys)	GDP Binding, GoLoco Binding	34	0.938 (PP)	9.041	0
5	chr7:g.79818282G>A	c.134G>A	p.(Gly45Asp)	GDP Binding	29.2	0.549 (PP)	9.75805	0
6 7 8	chr7:g.79818291C>A	c.143C>A	p.(Thr48Lys)	GDP Binding	32	0.432 (PP)	7.6889	0
9 10	chr7:g.79818291C>T	c.143 C>T	p.(Thr48Ile)	GDP Binding	32	0.329 (PP)	7.6889	0
11	chr7:g.79818303A>C	c.155A>C	p.(Gln52Pro)	none	27.4	0.534 (PP)	9.29824	0
12	chr7:g.79818466_79818468del	c.222_224del	p.(Ser75del)	GoLoco Binding	NA	NA	9.29824	0
13 14	chr7:g.79833072_79833074del	c.514_516del	p.(Gln172del)	none	NA	NA	9.1759	0
15	chr7:g.79833076A>T	c.518A>T	p.(Asp173Val)	GDP Binding	29.8	0.255 (PP)	9.1759	0
16	chr7:g.79833114_79833125del	c.556_567del	p.(Glu186_Phe189del)	none	NA	NA	9.1759	0
17 18	chr7:g.79840365G>A	c.671G>A	p.(Cys224Tyr)	none	29.2	0.309 (PP)	9.818	0
19 20	chr7:g.79842120A>G	c.809A>G	p.(Lys270Arg)	GDP Binding	32	0.611 (PP)	9.24465	0
21	chr7:79842121G>C	c.810G>C	p.(Lys270Asn)	GDP Binding	27.5	0.596 (PP)	6.72193	0
22	chr7:g.79842143dup	c.832dupA	p.(Ile278Asnfs*20)	NA	NA	NA	6.26325	0
23	chr7:g.79846720G>C	c.976G>C	p.(Ala326Pro)	GDP Binding	28.6	0.606 (PP)	9.818	0
24	chr7:g.79846739T>A	c.995T>A	p.(Val332Glu)	none	27.6	0.540 (PP)	7.98329	0

Abbreviations: AC, allele count; GDP, Guanosine-diphosphate; NA, not applicable; PP, possibly pathogenic

Table 2:

Summary of clinical features of individuals with *de novo* variants in *GNAT1*

Individual	Sex	Variant	DD	Delayed Sitting	Delayed Walking	Language Delays	Intellectual Disabilities	Autism	Seizures	Tone	MRI anomalies
1	M	p.(Gly40Arg)	+	nr	nr	nr	nr	+	+	Hypotonia	+
2	F	p.(Gly40Arg) ^A	+	nr	-	-	-	+	-	Hypotonia	nr
3	M	p.(Gly40Cys)	+	nr	+	Nonverbal	S	+	+	Normal	+
4	F	p.(Gly40Cys)	P	Not achieved	Not achieved	Nonverbal	S	nr	+	Hypertonia	+
5	M	p.(Gly45Asp)	+	+	+	Nonverbal	nr	+	+	Hypotonia	-
6	F	p.(Thr48Lys)	+	+	+	Nonverbal	P	-	+	Hypotonia	+
7	M	p.(Thr48Lys)	+	+	Not achieved	Nonverbal	nr	-	+	Hypotonia	nr
8	M	p.(Thr48Lys)	P	Not achieved	Not achieved	Nonverbal	P	nr	+	Hypotonia	+
9	M	p.(Thr48Ile)	+	+	-	Nonverbal	S	+	-	Hypotonia	-
10	F	p.(Thr48Ile)	+	-	+	+	nr	-	-	Hypotonia	-
11	M	p.(Gln52Pro)	+	+	Not achieved	Nonverbal	S	+	+	Hypotonia	+
12	F	p.(Ser75del)	S	+	Not achieved	Nonverbal	S-P	-	+	Hypotonia	-
13	M	p.(Gln172del)	P	Not achieved	Not achieved	Nonverbal	S-P	-	+	Hypotonia	+
14	F	p.(Gln172del)	+	+	-	Nonverbal	S	-	-	nr	nr
15	F	p.(Asp173Val)	+	-	+	+	Mi	-	+	Hypotonia	-
16	F	p.(Glu186_Phe189del)	+	-	+	Nonverbal	+	-	nr	Hypotonia	nr
17	F	p.(Cys224Tyr)	Mo-S	+	-	+	Mo-S	-	+	Hypotonia	-
18	F	p.(Cys224Tyr)	+	+	+	-	Mo	+	-	Hypotonia	-
19	F	p.(Lys270Arg)	+	+	+	+	Mo	-	+	Hypotonia	-
20	M	p.(Lys270Arg)	+	+	+	Nonverbal	S	-	+	Hypotonia	-
21	M	p.(Lys270Asn)	+	Not achieved	Not achieved	Nonverbal	Mo	-	+	Hypotonia	+
22	F	p.(Ile278AsnfsX20)	P	Not achieved	Not achieved	Nonverbal	S-P	-	+	Hypotonia	+
23	F	p.(Ala326Pro)	+	+	+	+	Mi	-	-	Hypotonia	-
24	F	p.(Val332Glu)	+	+	Not achieved	Nonverbal	+	nr	+	Hypertonia	+
Totals			24/24	18/21	19/23	21/23	20/20	7/21	17/23	22/23	10/20

Abbreviations: DD, Developmental Delay; F, female; M, male; Mi, mild; Mo, moderate; nr, not reported; S, severe; P, profound; +, present; -, absent

somatic mosaic variant.
^

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript